Cyntegrity Germany GmbH and PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft (PwC) have entered into a cooperation agreement to offer innovative and complementary services to clients in the pharmaceutical industry. Cyntegrity’s cloud-based technology solution, the MyRBQM Portal, a risk-based quality management (RBQM) system, enables companies to improve their clinical operations, manage risks within clinical research activities, and speed up drug development and approval. PwC, one of Germany’s leading audit and consulting firms, is well-positioned to support companies in the pharmaceutical, biotech, and medical device industries with its expertise in professional services, data integration, and M&A activities.

This cooperation brings together the best of both worlds: Cyntegrity’s cutting-edge risk-management technology solutions, including the MyRBQM Portal and its AI-driven modules such as Predictive Analytics, Centralized Statistical Monitoring and Patient Profiles, and PwC’s expertise in professional services and data integration in the healthcare and pharmaceutical sectors. The MyRBQM Portal’s portfolio oversight capabilities can be used by PwC clients during M&A activities to ensure sponsor compliance and minimize vendor risks. Furthermore, this cooperation enables PwC to highlight areas of business opportunity in the drug development portfolio for its clients.

"Together with PwC, we are excited to bring our expertise in data science and AI to enhance the clinical trial process and improve patient safety. This cooperation will allow us to offer our clients a unique solution that combines the power of cutting-edge technology with the knowledge and experience of a leading professional services firm," said Artem Andrianov, Ph.D., CEO of Cyntegrity.

“Our risk enablement has technology at its heart where we strive to diversify from pure services to include a combination of products, platforms, tech-enabled and managed services. We are excited about this opportunity to cooperate with Cyntegrity which offers a risk-based quality management solution for the BioPharma industry and helps our customers to manage complex regulations and business risks,” said Dr. Robert Paffen, Risk & Regulatory Leader, PwC Germany. “In an evolving global risk market, regulations and compliance management remains a priority to manage the business risks landscape. Data and tech-integrated digital solutions help carry out this compliance transformation for our Pharma and Healthcare customers. We are delighted to announce the cooperation with Cyntegrity that helps our customers streamline and optimize their clinical operations along with our expertise in professional services, and data integration can further enhance the implementation and success of the R&D ecosystem,” added Steffen Esche, Risk & Regulatory Pharma Life Science Compliance Lead, PwC Germany.

About Cyntegrity: Cyntegrity is a leading provider of innovative cloud-based technology solutions for the pharmaceutical industry. The company’s MyRBQM® Portal, a risk-based quality management system, and MyRBQM® Academy, a comprehensive education platform, empower companies to improve their clinical operations, better manage risks within clinical research activities and speed up drug development and approval. The MyRBQM Academy helps companies embrace a quality-by-design (QbD) culture by providing education that helps study teams grasp and reap the benefits of risk-based trial management, ensuring full adoption and compliance.

About PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft: PwC’s clients face diverse challenges, strive to put new ideas into practice, and seek expert advice. They turn to PwC for comprehensive support and practical solutions that deliver maximum value. Whether for a global player, a family business, or a public institution, PwC leverages all of its assets: experience, industry knowledge, high standards of quality, commitment to innovation, and the resources of its expert network in 152 countries. Building a trusting and cooperative relationship with their clients is particularly important to them.

Über die Cyntegrity Germany GmbH

Cyntegrity is a leading intelligent risk-based quality management (RBQM) solutions provider in the BioPharma industry, applying risk-based strategies to manage patient safety and data quality, through it’s innovative and highly rated MyRBQM® Portal and MyRBQM® Academy platforms. Through these platforms, Cyntegrity supports sponsors, CROs, and auditors with data science technology and related educational programs to focus clinical operations resources on the locations and activities where they are most needed.

Cyntegrity is a fast-growing scale-up company staffed by an international team of industry experts, representing over 17 nationalities living in 14 countries.

Cyntegrity’s mission is to become the first-choice provider of AI-driven SaaS and PaaS solutions for ICH GCP-compliant clinical trial risk management and risk-based regulatory oversight and surveillance.

Firmenkontakt und Herausgeber der Meldung:

Cyntegrity Germany GmbH
Altenhöferallee 3
60438 Frankfurt am Main
Telefon: +49 (0) 6192-470-113-50
https://cyntegrity.com/

Ansprechpartner:
Marketing department of Cyntegrity
Telefon: +49 (0) 619247011350
E-Mail: marketing@cyntegrity.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel